Navigation Links
BUSM researcher awarded 2 NIH grants totaling over $11 million
Date:11/2/2011

(Boston) - Boston University School of Medicine (BUSM) researcher Robert Lafyatis, MD, recently was awarded two grants from the National Institutes of Health's (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases. A 5-year, $8 million Centers of Research Translation (CORT) (P50) grant as well as a 5-year $3.3 million (P30) grant. Funding from both grants will be used to study systemic sclerosis (SSc) also known as scleroderma, a rare and complex rheumatic disease involving widespread scarring and vascular disease within multiple organ systems.

SSc remains one of the most difficult rheumatic diseases to manage, with limited effective therapies. These projects were designed to coordinate multiple scientists and clinicians to accelerate the understanding of the disease process through interactive patient-oriented studies into markers of disease activity, investigation of pathogenesis and trials of novel therapeutics.

The P50 grant will fund clinical research, identifying new paradigms for early phase clinical trials and molecular research into scleroderma pathogenesis. The P30 will allow the researchers at four sites: BUSM, University of Pittsburg Medical Center, Northwestern School of Medicine and Dartmouth Medical Center, to set up core services for scleroderma research, with the ultimate goal being a national resource for investigators studying scleroderma across the country.

One of the greatest impediments to finding new treatments is the heterogeneity of patient presentation and disease progression. Clinical markers are unable to predict onset and/or progression of the major complications, such as progressive fibrotic skin disease, pulmonary arterial hypertension and interstitial lung disease, each seen in a minority of SSc patients.

According to the researchers, identification of biomarkers permitting early recognition of these complications would potentially permit more targeted therapies, but also provide "at risk" populations for enrolling in therapeutic trials.

"Empowered by a very large SSc clinical population, we propose careful clinical evaluations, coupled with robust molecular approaches to identify skin, serum and peripheral blood mononuclear cell disease biomarkers," explained principal investigator Lafyatis, who also is a professor of medicine at BUSM.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Tiny fruit fly could offer big clues in fight against obesity, researcher says
6. Researchers create drug to keep tumor growth switched off
7. MSU researcher linking breast cancer patients with alternative therapies
8. UT researcher receives $2.4 million to research obesity, high-risk pregnancy
9. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
10. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
11. Clemson researchers develop hands-free texting application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... York, NY (PRWEB) , ... December 02, 2016 ... ... featuring an inspirational interview of two ostomy patients, standing as living proof that ... people suffer from digestive diseases and issues that spike around the holidays. This ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference ... and Spa in Honolulu, offering local frontline clinicians the opportunity to extend their ... The demand for supplemental training related to pain management has surged dramatically in ...
(Date:12/2/2016)... , ... December 02, 2016 , ... "Pro3rd Accents Volume ... editors to create versatile lower third titles with just a few clicks of the ... Volume 2 includes 30 lower third animations. Choose from various styles with accented animations, ...
(Date:12/2/2016)... FL (PRWEB) , ... December 02, 2016 , ... ‘Tis ... are winners of $1,000 each from the National Family Partnership and the Drug Enforcement ... families who decorated their homes and the 10 winning schools who decorated their campuses ...
(Date:11/30/2016)... Beach Gardens, FL (PRWEB) , ... November 30, ... ... in eating disorder and mental health treatment has announced the opening of a ... provides specialized partial hospitalization and intensive outpatient treatment for adults and adolescents, both ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 Orthopedic Implants (Including Spinal Implants, ... to Gain a Significant Market Share Owing to a Large ... ... According to a new report by Persistence ... Packaging: Clamshell Product Type Segment Projected to Witness a Significantly ...
(Date:12/2/2016)... , Dec. 2, 2016   CytoSorbents Corporation ... commercializing its European Union approved CytoSorb ® cytokine ... surgery patients worldwide, announced that Dr. Phillip Chan ... 9th Annual LD Micro Main Event investor conference ... at the Luxe Sunset Boulevard Hotel in ...
(Date:12/2/2016)... On Thursday, the NASDAQ Composite ended the trading ... edged 0.36% higher, to finish at 19,191.93; and the S&P ... as six out of nine sectors ended the day in ... Services equities: Myriad Genetics Inc. (NASDAQ: MYGN ), ... Inc. (NASDAQ: INCR ), and La Quinta Holdings ...
Breaking Medicine Technology: